SAN CARLOS, Calif., May 22, 2026
Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused on non-viral DNA delivery technologies, in a deal valued at up to $202 million, strengthening Lilly’s expanding genetic medicines portfolio and accelerating development of next-generation nucleic acid therapies. The acquisition combines Lilly’s growing capabilities in genetic medicine development with Engage Bio’s proprietary Tethosome platform, a novel non-viral DNA delivery system engineered to improve the potency, tolerability, and redosability of DNA-based therapeutics. The transaction highlights the increasing pharmaceutical industry focus on advanced gene delivery technologies designed to overcome long-standing limitations associated with genetic medicines and precision therapeutics.
Lilly Expands Non-Viral Genetic Medicine Capabilities
Engage Bio’s innovative Tethosome platform is designed to address several major barriers that have historically limited the effectiveness of non-viral DNA therapies, including poor nuclear localization, immune sensing challenges, limited repeat dosing potential, and insufficient therapeutic expression. The platform integrates engineered DNA payloads with lipid nanoparticle (LNP) delivery systems and proprietary mRNA-encoded Tethosome technology intended to enhance intracellular localization and improve gene expression efficiency.
According to the companies, Engage’s DNA payloads are further engineered to improve tolerability while preserving key advantages of DNA-based therapies such as durability, programmability, and flexible therapeutic design. Industry experts continue to identify non-viral gene delivery systems as one of the most promising frontiers in biotechnology because they may offer safer and more scalable alternatives to viral vector-based therapies currently used in many gene therapy programs.
Under the terms of the agreement, Lilly acquired Engage Bio for up to $202 million in cash, including an upfront payment and additional milestone-based payments tied to future development achievements. The acquisition strengthens Lilly’s broader strategy of investing aggressively in next-generation therapeutic platforms across genetic medicine, RNA technologies, and precision biotechnology.
Advertisement
Engage Bio Platform Targets Next-Generation Therapies
Founded in 2021 and headquartered in California, Engage Bio has rapidly advanced its non-viral DNA delivery technologies through a lean development model supported by seed investors, biotechnology accelerators, and non-dilutive research funding. The company has received support from organizations including the Gates Foundation, NIH-NCATS, Y Combinator, SciFounders, and the Cystic Fibrosis Foundation, reflecting growing scientific confidence in its platform potential.
Will Olsen, Co-Founder and Chief Executive Officer of Engage Bio, stated that the company’s rapid progress demonstrates how synthetic biology and focused innovation can create transformative new therapeutic approaches even within early-stage biotechnology environments. He noted that combining Engage’s Tethosome platform with Lilly’s extensive research, development, and manufacturing capabilities could significantly accelerate the development of novel genetic therapies targeting serious diseases with unmet medical needs.
The acquisition also reinforces Lilly’s reputation as one of the pharmaceutical industry’s most active investors in advanced biotechnology platforms, particularly within areas such as gene editing, RNA therapeutics, obesity medicine, neurodegeneration, and precision oncology. Industry analysts continue to identify genetic medicines as one of the fastest-growing sectors in biopharmaceutical innovation due to their potential to deliver long-lasting and highly targeted treatment effects.
Genetic Medicines Continue Driving Biopharma Innovation
The deal reflects broader industry momentum toward next-generation genetic medicine technologies capable of improving therapeutic delivery, reducing toxicity, and enabling repeat dosing strategies. Pharmaceutical companies globally are increasingly pursuing acquisitions, partnerships, and platform investments involving nucleic acid delivery systems, lipid nanoparticles, synthetic biology, and programmable therapeutic technologies as competition intensifies across the biotechnology landscape.
Non-viral delivery approaches are attracting particular interest because they may overcome several manufacturing, safety, and immunogenicity limitations associated with viral vector platforms. Advances in lipid nanoparticle engineering and mRNA technologies, accelerated during recent years, have further expanded commercial and scientific interest in DNA and RNA therapeutic development.
The acquisition of Engage Bio positions Lilly to strengthen its long-term leadership within the rapidly evolving genetic medicines sector while advancing innovative therapeutic technologies designed to support the future of precision medicine and next-generation biotechnology innovation.
Source: Eli Lilly, Engage Bio press release
